Conv. Plasma
Nigella Sativa

All ivermectin studies
Meta analysis
study COVID-19 treatment researchIvermectinIvermectin (more..)
Melatonin Meta
Azvudine Meta Metformin Meta
Bromhexine Meta
Budesonide Meta Molnupiravir Meta
Colchicine Meta
Conv. Plasma Meta
Curcumin Meta Nigella Sativa Meta
Famotidine Meta Nitazoxanide Meta
Favipiravir Meta Paxlovid Meta
Fluvoxamine Meta Quercetin Meta
Hydroxychlor.. Meta Remdesivir Meta
Ivermectin Meta
Lactoferrin Meta

All Studies   Meta Analysis   Recent:  
0 0.5 1 1.5 2+ Mortality 57% Improvement Relative Risk Ventilation -34% ICU admission -37% primary Ivermectin  Ochoa-Jaramillo et al.  LATE TREATMENT  DB RCT Is late treatment with ivermectin beneficial for COVID-19? Double-blind RCT 75 patients in Colombia (December 2020 - December 2021) Lower mortality (p=0.35) and higher ICU admission (p=0.52), not sig. Ochoa-Jaramillo et al., Revista Infectio, Oct 2022 Favors ivermectin Favors control

Clinical efficacy and safety of ivermectin (400 μg/kg, single dose) in patients with severe COVID-19: a randomized clinical trial

Ochoa-Jaramillo et al., Revista Infectio, NCT04602507
Oct 2022  
  Source   PDF   All Studies   Meta AnalysisMeta
RCT 75 very late stage patients in Colombia, showing no significant difference in outcomes with a single dose of 400μg/kg ivermectin.
Although the 57% lower mortality is not statistically significant, it is consistent with the significant 49% lower mortality [35‑60%] from meta analysis of the 51 mortality results to date.
This is the 43rd of 46 COVID-19 RCTs for ivermectin, which collectively show efficacy with p=0.00000014.
This is the 93rd of 99 COVID-19 controlled studies for ivermectin, which collectively show efficacy with p<0.0000000001 (1 in 2 sextillion).
risk of death, 57.0% lower, HR 0.43, p = 0.35, treatment 2 of 37 (5.4%), control 4 of 38 (10.5%), NNT 20, Cox proportional hazards.
risk of mechanical ventilation, 34.0% higher, HR 1.34, p = 0.62, treatment 7 of 37 (18.9%), control 5 of 38 (13.2%), Cox proportional hazards.
risk of ICU admission, 37.0% higher, HR 1.37, p = 0.52, treatment 8 of 37 (21.6%), control 6 of 38 (15.8%), Cox proportional hazards, primary outcome.
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
Ochoa-Jaramillo et al., 21 Oct 2022, Double Blind Randomized Controlled Trial, placebo-controlled, Colombia, peer-reviewed, 8 authors, study period 10 December, 2020 - 9 December, 2021, average treatment delay 8.8 days, dosage 400μg/kg single dose, trial NCT04602507 (history).
All Studies   Meta Analysis   Submit Updates or Corrections
This PaperIvermectinAll
Clinical efficacy and safety of ivermectin (400 μg/kg, single dose) in patients with severe COVID-19: a randomized clinical trial
Francisco Ochoa-Jaramillo, Nora Cardona-Castro, Federico Rodriguez-Vega, Veronica Posada-Velez, Diego Rojas-Gual- Dron, Heidy Contreras-Martinez, Ana Romero-Millan, Jessica Porras-Mansilla
Purpose: To evaluate the clinical efficacy of including Ivermectin (single dose on day 1 of 400 μg/kg PO) in the standard of care in hospitalized adults with severe COVID-19. Methods: Double-blinded, parallel, placebo-controlled, single-center, randomized clinical trial. Seventy-five patients were randomly assigned (1:1) to receive standard of care plus ivermectin or placebo and were followed up for 21 days. Primary outcome measure was admission to ICU and secondary outcomes were the requirement of intensive mechanical ventilation (IMV) and in-hospital death. Intention-to-treat analyses, estimated risk differences (RD), and Hazard ratios (HR) with Cox regression were performed. Results: Enrollment stopped due to the lack of eligible patients. Thirty-seven patients were assigned to intervention and 38 to placebo. Patients in the ivermectin group were 54.5 years on average, 62.2% were male. Comorbidities were more prevalent in the control group (78.9% vs. 56.8%). There was no difference in the 21-day risk of admission to the ICU between ivermectin (21.6%) and placebo (15.8%) (RD= 5.8%; 95%CI: -11.8%-23.5%); neither in the risk of requirement of IMV (18.9% vs 13.2%), mortality (5.4% vs 10.5%) or in adverse events (32.4% vs. 28.9%). Discussion: Ivermectin showed no significant benefit in reducing the requirement of ICU, IMV, or mortality for severe COVID-19 patients.
Financial Support. The study was supported by Fundación Cerro Matoso, Mineros SA, Servicios Generales Suramericana S.A.S., and the Direction of Research CES University. None of the funding sources had any direct or indirect involvement in the study's design, conduct, and completion. Declarations of interest. None. Author statement.
Arshad, Pertinez, Box, Tatham, Rajoli et al., Prioritization of Anti-SARS-Cov-2 Drug Repurposing Opportunities Based on Plasma and Target Site Concentrations Derived from their Established Human Pharmacokinetics, Clin Pharmacol Ther, doi:10.1002/cpt.1909
Caly, Druce, Catton, Jans, Wagstaff, The FDA-approved drug ivermectin inhibits the replication of SARS-CoV-2 in vitro, Antiviral Res, doi:10.1016/j.antiviral.2020.104787
Canga, Prieto, Liébana, Martínez, Vega et al., The Pharmacokinetics and Interactions of Ivermectin in Humans-A Mini-review, AAPS J, doi:10.1208/s12248-007-9000-9
Chaccour, Casellas, Blanco-Di Matteo, Pineda, Fernandez-Montero et al., The effect of early treatment with ivermectin on viral load, symptoms and humoral response in patients with nonsevere COVID-19: A pilot, double-blind, placebo-controlled, randomized clinical trial, EClinicalMedicine, doi:10.1016/j.eclinm.2020.100720
Ci, Li, Yu, Zhang, Yu et al., Avermectin exerts antiinflammatory effect by downregulating the nuclear transcription factor kappa-B and mitogen-activated protein kinase activation pathway, Fundam Clin Pharmacol, doi:10.1111/j.1472-8206.2009.00684
Crump, Ivermectin: enigmatic multifaceted 'wonder' drug continues to surprise and exceed expectations, J Antibiot, doi:10.1038/ja.2017.11
De Melo, Lazarini, Larrous, Feige, Kergoat et al., Anti-COVID-19 efficacy of ivermectin in the golden hamster, Immunology, doi:10.1101/2020.11.21.392639
Gonzalez, Gámez, Enciso, Maldonado, Palacios et al., Efficacy and safety of Ivermectin and Hydroxychloroquine in patients with severe COVID-19. A randomized controlled trial, doi:10.1101/2021.02.18.21252037
Hill, Mirchandani, Pilkington, Ivermectin for COVID-19: Addressing Potential Bias and Medical Fraud, Open Forum Infectious Diseases, doi:10.1093/ofid/ofab645
Hill, Wang, Levi, Heath, Fortunak, Minimum costs to manufacture new treatments for COVID-19, J Virus Erad, doi:10.1016/S2055-6640(20)30018-2
Jermain, Hanafin, Cao, Lifschitz, Lanusse et al., Development of a minimal physiologically-based pharmacokinetic model to simulate lung exposure in humans following oral administration of ivermectin for COVID-19 Drug Repurposing, J Pharm Sci, doi:10.1016/j.xphs.2020.08.024
Kircik, Rosso, Layton, Schauber, Over 25 Years of Clinical Experience With Ivermectin: An Overview of Safety for an Increasing Number of Indications, J Drugs Dermatol
Lehrer, Rheinstein, Ivermectin Docks to the SARS-CoV-2 Spike Receptor-binding Domain Attached to ACE2, Vivo, doi:10.21873/invivo.12134
Mohan, Tiwari, Suri, Mittal, Patel et al., Single-dose oral ivermectin in mild and moderate COVID-19 (RIVET-COV): A singlecentre randomized, placebo-controlled trial, J Infect Chemother, doi:10.1016/j.jiac.2021.08.021
Rizzo, Ivermectin, antiviral properties and COVID-19: a possible new mechanism of action, Naunyn Schmiedebergs Arch Pharm, doi:10.1007/s00210-020-01902-5
Schulz, Altman, Moher, Statement: updated guidelines for reporting parallel group randomised trials, BMC Med, doi:10.1186/1741-7015-8-18
Trujillo, Consenso colombiano de atención, diagnóstico y manejo de la infección por SARS-COV-2/COVID 19 en establecimientos de atención de la salud. Recomendaciones basadas en consenso de expertos e informadas en la evidencia, Infectio, doi:10.22354/in.v24i3.851
Ventre, Rozières, Lenief, Albert, Rossio et al., Topical ivermectin improves allergic skin inflammation, Allergy, doi:10.1111/all.13118
Wehbe, Wehbe, Iratni, Pintus, Zaraket et al., Repurposing Ivermectin for COVID-19: Molecular Aspects and Therapeutic Possibilities, Front Immunol, doi:10.3389/fimmu.2021.663586
Who, Inchem, International Peer Reviewed Chemical Safety Information
Yan, Ci, Chen, Chen, Li et al., Anti-inflammatory effects of ivermectin in mouse model of allergic asthma, Inflamm Res, doi:10.1007/s00011-011-0307-8
Zhang, Song, Ci, Ju, Li, Ivermectin inhibits LPSinduced production of inflammatory cytokines and improves LPS-induced survival in mice, Inflamm Res, doi:10.1007/s00011-008-8007-8
Zhang, Song, Xiong, Ci, Li et al., Inhibitory effects of ivermectin on nitric oxide and prostaglandin E2 production in LPS-stimulated RAW 264.7 macrophages, Int Immunopharmacol, doi:10.1016/j.intimp.2008.12.016
Late treatment
is less effective
Please send us corrections, updates, or comments. c19early involves the extraction of over 100,000 datapoints from thousands of papers. Community updates help ensure high accuracy. Vaccines and treatments are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop